<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01239719</url>
  </required_header>
  <id_info>
    <org_study_id>DECEMS11209</org_study_id>
    <secondary_id>Version 02 - Amendment 02</secondary_id>
    <nct_id>NCT01239719</nct_id>
  </id_info>
  <brief_title>Randomized Study for Effectiveness and Safety Evaluation of Dexamethasone 0.5 mg + Fumarate Clemastine 1 mg Compared to Dexamethasone 0.5 mg in Patients With Allergic Dermatitis</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Azidus Brasil</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Azidus Brasil</source>
  <brief_summary>
    <textblock>
      The aim of this study is to prove the efficacy of the dexamethasone 0.5 mg + 1 mg clemastine
      fumarate tablet compared to 0.5 mg of dexamethasone in reducing the signs and symptoms of
      allergic dermatitis.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>March 2011</start_date>
  <completion_date type="Anticipated">December 2011</completion_date>
  <primary_completion_date type="Anticipated">July 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate, through clinical examinations, the effectiveness of the combination tablet with 0.5 mg of dexamethasone and clemastine 1 mg, compared with 0.5 mg tablet of dexamethasone in improving the signs and symptoms associated with allergic dermatitis.</measure>
    <time_frame>14 days of treatment.</time_frame>
    <description>Evaluating the effectiveness of the polypill dexamethasone 0.5 mg + 1 mg clemastine fumarate tablet compared to 0.5 mg of dexamethasone in improvement of signs (erythema, edema and lesion length) and symptoms (itching) associated with frames of dermatoses allergic.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the efficacy.</measure>
    <time_frame>14 days of treatment.</time_frame>
    <description>Constitute secondary signals of efficacy including excoriation, oozing, crusting and lichenification.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">96</enrollment>
  <condition>Allergy</condition>
  <condition>Dermatitis</condition>
  <arm_group>
    <arm_group_label>Dexamethasone + Clemastine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dexamethasone + clemastine fumarate cream</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dexamethasone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dexamethasone 0.5 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone + clemastine</intervention_name>
    <description>Dexamethasone 0.5 mg clemastine fumarate: 01 tablet every 12 hours.</description>
    <arm_group_label>Dexamethasone + Clemastine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>Dexamethasone 0.5 mg: 01 tablet every 12 hours.</description>
    <arm_group_label>Dexamethasone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients who sign the IC in two ways, agreeing with all study procedures

          -  Patients aged above 18 years of any ethnicity, class or social group, female or male

          -  Patients with acute, subacute or chronic dermatoses, of inflammatory and / or allergic
             origin, to which it is recommended the use of drugs under investigation, such as:

               -  atopic dermatitis

               -  prurigo

               -  primary contact dermatitis or allergic hives

               -  drug eruption

               -  allergic vasculitis

               -  dyshidrosis, Note: The above clinical conditions are diagnosed from clinical
                  examination.

        Exclusion Criteria:

          -  Patients being treated with antibiotics

          -  Participation in clinical trials in the 12 months preceding the investigation

          -  Current treatment with immunosuppressants (eg, cyclosporine or methotrexate)

          -  Current treatment with phototherapy (UVA, UVB, PUVA and lasers)

          -  Use of systemic corticosteroids in the visit to include or 15 days preceding the
             survey

          -  Topical treatments at the site of lesions in the 15 days preceding the survey

          -  Presence of any skin condition

          -  Presence of secondary infections at the site of treatment, diagnosed clinically;

          -  Presence of other eczematous diseases, such as nummular eczema, neurodermatitis,
             seborrheic dermatitis, psoriasis, scabies, and Buckley's syndrome

          -  Pregnant or lactating women

          -  Chronic alcoholism

          -  Patients with a history of hypersensitivity to any component of the products under
             investigation.

          -  Any finding of clinical observation (clinical history or physical examination) that is
             interpreted by the physician investigator as a risk to the patient's participation in
             the study.

          -  Allergic Dermatosis mild or, acording to the investigator criteria, is not justified
             systemic treatment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Alexandre Frederico, Physician</last_name>
    <phone>55 19 3829-3822</phone>
    <email>alexandre@lalclinica.com.br</email>
  </overall_contact>
  <verification_date>January 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 8, 2010</study_first_submitted>
  <study_first_submitted_qc>November 10, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 11, 2010</study_first_posted>
  <last_update_submitted>January 27, 2011</last_update_submitted>
  <last_update_submitted_qc>January 27, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 28, 2011</last_update_posted>
  <responsible_party>
    <name_title>Alexandre Frederico</name_title>
    <organization>LAL Cl√≠nica</organization>
  </responsible_party>
  <keyword>Allergic dermatitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Dermatitis, Atopic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>BB 1101</mesh_term>
    <mesh_term>Clemastine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

